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A B S T R A C T   
Background: The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated 
factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices 
for asthma patients who initiated inhalation therapy. 
Methods: We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients 
commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised 
metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device 
and multivariate analysis was used to model the likelihood of receiving a pMDI as opposed to a DPI in order to 
identify drivers for prescription. A sample of the respiratory specialists completed an ad-hoc survey of their 
perceived success in achieving asthma control in their patients and barriers to attaining full control. 
Results: Prescription of a particular inhaler device was unrelated to the characteristics of the patients. Multi-
variate analysis revealed that the main driver for the choice of inhaler device choice was the medication (Odds 
Ratio and 95% Confidence Interval, respectively for GPs and specialists: 0.19 [0.16–0.23]; 0.17 [0.08–0.37]). 
Specialists perceived asthma as being inadequately controlled in 41% of their patients, and considered patients’ 
difficulties in using DPIs and pMDIs as instrumental in this, citing a need for a novel, more effective inhaler 
technology. 
Conclusion: Physicians choose inhaler devices according to the prescribed drugs and not to the characteristics of 
the individual patient. This may reflect a lack of confidence in existing inhaler devices and underlines the need 
for technologies, which are more reliable and easier to use by patients.   
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1. Introduction 
Current asthma guidelines recommend inhaled corticosteroid and 
long-acting β2-agonist (ICS/LABA) fixed-dose medications as controller 
medication for the management of patients with moderate (i.e. step 3 
and 4) disease [1]. Although ICS/LABA medications have been shown to 
relieve asthma symptoms [2,3], they need to be delivered regularly and 
in sufficient quantities to the airways in order to be effective. Subopti-
mal adherence to inhaled medications continues to be a significant 
barrier to asthma control, contributing to the deterioration of symptoms 
and quality of life as well as costly exacerbations over time [4,5]. Good 
adherence in turn requires patients’ acceptance of their need for regular 
and continuous inhaled therapy, together with the successful mastery of 
the inhaler technique specific to their device(s) [5]. Accumulating evi-
dence now suggests that the quality of inhaler technique itself influences 
adherence: indeed one might anticipate that patients are less likely to 
adhere to a treatment that they find apparently ineffective because they 
cannot or do not use it properly [6–9]. Thus, devices used for inhalation 
therapy in asthma may critically affect outcomes, through both poor 
drug delivery and poor adherence, independently of the actual medi-
cation used [5]. The effectiveness of any individual device in delivering 
the contained drug(s) to the airways may depend on several factors, 
mainly its ability to deliver, by inhalation, a sufficient respirable fraction 
of the delivered drug(s) to the airways reproducibly, precisely and stably 
over time [9,10]. Ease of use may also be critical, particularly in patients 
at the extremes of age, those with physical disabilities and those with 
limited inspiratory capacity [9,10]. The wide variety of inhaler devices 
now available presents both opportunities and challenges for patients 
and prescribers. Indeed, in addition to the broad and fundamental dif-
ferences in the correct usage of pressurised, metered-dose inhalers 
(pMDIs) and dry powder inhalers (DPIs), every single device within 
these categories may require specific nuances to optimize continued, 
optimal and sufficient drug delivery [9,10]. Both types of device are 
available to deliver ICS/LABA combination therapy: pMDIs are widely 
prescribed because of their low cost, and use consistent technology to 
deliver a variety of medications relatively independently of inhalational 
effort [9,10]. However, they require coordination of inhaler actuation 
and inhalation, and although this can often be accomplished relatively 
easily with a spacer device, there is room for error even after repeated, 
appropriate training [11]. In contrast, DPIs do not require coordination 
of inhaler actuation with inhalation since they are actuated by the pa-
tient’s inspiratory flow [9,10,12]. The very fact that DPIs are inspiratory 
flow driven does however necessitate a forceful and deep inhalation to 
de-agglomerate the powder formulation into respirable particles to 
ensure that drug is delivered to the lungs [12]. Therefore, DPIs may not 
be effective for the treatment of patients with severe airflow limitation 
[13]. 
Despite studies highlighting the importance when treating asthma by 
tailoring devices to the individual characteristics of each patient 
[14–16], in the “real world” the choice of device appears to be governed 
principally by the type of medication used [17,18]. In practice, the 
choice of a therapeutic agent and the device used to deliver it lie with the 
prescribing physician and should strike a balance between appropriate 
medication and selection of the inhalation device [19]. It has to be taken 
into consideration that the choice of the most appropriate inhaler device 
for each patient has been claimed to be as critical as the choice of 
medication itself [15].Thus, the prescriber should be able to tailor the 
selection of the device to the individual patient, evaluating needs, 
functional ability, and the complexity of the medication regimen [19]. 
Given the key role of inhaler devices and healthcare providers in the 
management of asthma, this study aimed to explore factors influencing 
the choice of inhaler device by general practitioners (GPs) and special-
ists when initiating therapy for asthma, using real-world data. We then 
surveyed a sample of specialists to understand their perception of 
currently available inhaler devices and novel inhaler technologies. A 
greater understanding of the relationship between patient 
characteristics and inhaler choice may facilitate efforts to identify pa-
tients at risk of incorrect inhaler usage, and in turn guide clinicians in 
prescribing, for each individual patient, a device that is most likely to be 
used correctly. 
2. Methods 
2.1. Study design and data collection 
We retrospectively investigated the characteristics of asthma pa-
tients prescribed different inhaler devices by interrogating the IQVIA 
Longitudinal Patient Database (LPD) and the IQVIA Patient Analyzer 
Database (PAD). IQVIA (www.iqvia.com) is an international healthcare 
information company specialising in the collection and interpretation of 
anonymous health information, and often the only source of information 
on aspects of medicinal use across the world. The IQVIA LPD is a 
computerized network of GPs from different European countries 
providing information to a centralised database on patients’ consulta-
tions and treatments. This database reflects the clinical practice of a 
national sample of GPs since it allows the collection and longitudinal 
analysis of data taken from patients’ records related to prescription 
practices and healthcare utilisation in everyday clinical practice. Drug 
prescriptions and medical diagnoses are both coded directly by GPs. 
Drug prescriptions comply with the Anatomical Therapeutic and 
Chemical (ATC) classification system, while medical diagnoses comply 
with the 9th edition of International Classification of Disease (ICD-9- 
CM). Currently, about 900 Italian GPs contribute to the IQVIA LPD, 
providing data from routinely collected records of ~1.2 million patients. 
The Italian IQVIA LPD has been shown to be a reliable source of infor-
mation in documented in a range of studies of different diseases 
[20–25], including respiratory diseases [26,27]. From the IQVIA LPD we 
retrieved data on patients coded in 2016 (the selection period) with a 
diagnosis of asthma (ICD-9-CM 493.xx) and at least one prescription of 
beclomethasone dipropionate (BDP)/formoterol or fluticasone/salme-
terol fixed dose combination (study cohort) delivered by either a DPI or 
by a pMDI. The study was restricted to these ICS/LABA combinations 
because, at the time of the study, they were the only ICL/LABA combi-
nations available as both pMDIs and DPIs. Patients who were prescribed 
both DPI and pMDI inhaler devices were excluded. For each patient, the 
date of the first BDP/formoterol or fluticasone/salmeterol prescription 
during the selection period was indicated as the Index Date. For each 
patient of each study group, we collected information on clinical char-
acteristics such as gender, age, body mass index (BMI), smoking history 
and relevant co-morbidities (i.e. cardiovascular or neurologic diseases, 
diabetes, dyslipidaemia, osteoporosis, gastro-oesophageal reflux, 
allergic rhinitis, sinusitis, nasal polyps, personality and non-psychotic 
mental disorders) during the 12 months preceding the Index Date. 
Spirometry testing, specialist examinations, prescriptions of oral corti-
costeroids, asthma-related antibiotics, exacerbation [1], hospitalisations 
or emergency room admissions for asthma were also collected during 
the 12 months after the Index Date. 
The IQVIA PAD contains data from asthma patients obtained by 
means of a web questionnaire administered to Italian pulmonologists 
who collected medical records of patients evaluated during a single 
week, thereby providing a snapshot of real-life clinical activity [27]. As 
for the LPD, from the IQVIA PAD we retrieved data from asthma patients 
initiating in 2016 treatment with a BDP/formoterol or a fluticasone/-
salmeterol combination administered by either a DPI or by a pMDI. 
Specialists were asked for information on patient characteristics, asthma 
severity and control, as well as spirometric data (i.e. forced expiratory 
volume in the first second (FEV1) and peak expiratory flow (PEF) 
measurements). 
We also planned an ad-hoc survey on a sample of the specialists who 
had participated in the IQVIA PAD to investigate their perception of the 
quality of asthma control attained by their patients, the reason(s) why 
asthma remained uncontrolled and factors influencing their prescription 
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of DPIs or pMDIs. The survey, based on a web questionnaire (see online 
supplement), also evaluated the specialists’ knowledge about currently 
available pMDIs and DPIs, and sought their opinion on the novel breath- 
triggered MDI K-haler® (Mundipharma International, UK), a new 
inhaler device that, due to its technology [28], may improve device 
usability by patients [29]. Additional details on the methods are re-
ported in the online supplement. 
2.2. Statistical analysis 
Analyses using IQVIA LPD and PAD data were stratified by device 
type (pMDI or DPI). Descriptive statistics were presented and Chi-square 
tests or T-tests for independent groups were applied to evaluate the 
association between device type and each collected variable, as appro-
priate. Multivariate logistic models were applied to evaluate factors that 
could influence device choice. Device type was set as the dependent 
variable, while covariates included age, gender, variables significantly 
associated with device type (following Chi-square or T-test analyses), 
and variables recommended from scientific literature to take account 
when choosing the device (when available). Finally, all variables 
collected through the ad-hoc web questionnaire were descriptively 
analysed according to the nature of the corresponding questions. In 
particular, qualitative variables were described using frequencies and 
percentages, while quantitative variables were described in terms of 
mean value and standard deviation. All analyses were performed on 
anonymised data using SAS software (Version 9.4). A p-value of <0.05 
was considered statistically significant. 
3. Results 
3.1. Baseline characteristics of patients from the GP and specialist 
databases 
The number of asthmatic patients meeting inclusion criteria were 
4979 for the IQVIA LPD study cohort and 660 for the IQVIA PAD study 
cohort. Overall, the proportion of patients prescribed a pMDI was higher 
than those prescribed a DPI in both GP (57.6% versus 42.4%) and 
specialist (57.4% versus 42.6%) databases. However, when comparing 
patients prescribed BDP/formoterol with those prescribed fluticasone/ 
salmeterol, we found that in both GP and specialist databases, signifi-
cantly more patients who were prescribed BDP/formoterol received a 
pMDI, whereas patients who were prescribed fluticasone/salmeterol 
more frequently received a DPI (Fig. 1, P always <0.05). Table 1 shows 
baseline (i.e. before initiating treatment with an ICS/LABA combina-
tion) characteristics of patients stratified by the device type prescribed. 
Overall, patients in the specialist database were younger and had fewer 
co-morbidities than those in the GP database. For both GPs’ and spe-
cialists’ patients, those receiving a DPI were slightly but significantly (P 
< 0.05) older than those receiving a pMDI. Patients prescribed DPIs by 
GPs had a slight but significantly (P < 0.05) higher BMI than those 
prescribed pMDIs. A higher proportion of smokers was observed among 
patients prescribed DPIs by specialists (29.89% vs. 9.91%, P < 0.05), 
while no differences in terms of comorbidities were observed between 
patients prescribed a pMDI and those prescribed a DPI in either cohort 
(Table 1). Finally, focusing on specialists’ patients, no differences in 
terms of FEV1 and PEF values were observed between the DPI and pMDI 
groups (data not shown). 
3.2. Multivariate regression to examine predictors of inhaler choice 
With regard to GPs’ patients, multivariate logistic analysis revealed 
that gender, age, and comorbidities did not influence the choice of 
inhaler device (Table 2). Higher BMI values appeared to result in a slight 
but significant (P < 0.05) increase in the likelihood of receiving a DPI, 
although this was clinically negligible (i.e. a 1 point increase in BMI 
corresponded to a 2% increase in the likelihood of receiving a DPI rather 
than a pMDI). Patients prescribed BDP/formoterol had a significantly (P 
< 0.05) lower likelihood of receiving a DPI rather than a pMDI when 
compared to patients prescribed fluticasone/salmeterol (about 80% 
less). 
Using the specialists’ database, both age and medication influenced 
the choice of device, while gender, co-morbidities, smoking and PEF had 
no effect. In particular, the likelihood of receiving a DPI increased ac-
cording to the age of the patient. However, the wide range in confidence 
intervals for odds ratio estimates seemed to suggest some variability in 
the prescribing behaviour of the specialists with regard to patients’ age. 
Again, a strong influence of the medication on device choice was 
observed, with an effect magnitude and direction similar to that 
observed for the GPs’ patients (Table 2). 
3.3. 12-Month follow-up on GPs’ patients stratified by type of device 
Table 3 reports information collected during the 12-month follow-up 
period following the initiation of the LABA/ICS treatment, for the GPs’ 
patients. No differences were observed between the pMDI and DPI 
groups in terms of resource utilisation (i.e. spirometry and specialist 
visit requests, hospitalisations) and exacerbations. The only exception 
was short-acting beta agonist (SABA) co-prescriptions, as the proportion 
of patients who received them was significantly higher for the DPI group 
than the pMDI group. Overall, the proportion of patients with spirom-
etry and/or specialist visit requests was quite low (about 15%), while 
the proportion of patients experiencing exacerbations was quite high 
(about 21%; Table 3). 
3.4. Specialists’ web-based ad-hoc survey on pMDIs and DPIs 
Fifty-one specialists across Italy participated in the ad-hoc survey. 
From medical records, asthma was regarded as not well controlled in 
Fig. 1. Proportion of patients stratified by ICS/LABA medication and device type prescribed by general practitioners (GPs) and specialists.  
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about 41% of their patients. Among possible causes for poor asthma 
control, low adherence to therapy was the option to which, on average, 
specialists assigned the greatest weight (42%), followed by difficulties in 
using inhaler devices (24%), and severity of the disease (11%). It is 
worth noting that, on average, 53% and 39% of patients using pMDIs 
were reported to experience difficulties in hand-breath coordination 
“often” or “sometimes”, respectively. On the other hand, 20% and 61% 
of the patients using DPIs displayed difficulties in inhaling strongly and 
deeply “often” or “sometimes”, respectively. Specialists reported that, 
because of the difficulties in using their inhaler devices, the proportion 
of patients not in their opinion receiving an adequate dose of the drug 
was, on average, 35% for those using a pMDI and 21% for those using a 
DPI (data not shown). Fig. 2 shows the level of agreement (the higher the 
score assigned, the higher the level of agreement) among specialists with 
regard to their opinion about currently available pMDIs and DPIs. Most 
of the specialists agreed that patients’ difficulties with currently avail-
able devices could be potential obstacles to achieve full adherence to 
treatment. Furthermore, the opportunity to prescribe new inhaler de-
vices that may overcome patients’ difficulties with current devices 
seemed to be a popular conception, with 63% of specialists showing a 
good or very good level (score 7) of agreement with this statement 
(Fig. 2). 
When asked to rank the most important characteristic that should be 
taken into account when choosing a particular device for an asthmatic 
patient, most (63%) of the specialists chose “easy use of the device” as 
being the most important characteristic (data not shown). Fig. 3 shows 
the mean scores that specialists assigned to various aspects to be 
considered when choosing an inhaler device for a patient. The drivers of 
prescriptions to which specialists assigned the highest scores were 
mainly related to those likely to improve patients’ adherence when 
using an inhaler device (Fig. 3). Furthermore, about 75% of the spe-
cialists agreed that the novel breath-triggered K-haler device might 
facilitate proper drug intake compared to pMDIs and DPIs; therefore, 
most of the specialists would likely (43%) or certainly (45%) be inclined 
to prescribe this novel inhaler device (data not shown). 
4. Discussion 
The present study investigated current “real-world” drivers of 
inhaler choice in asthma patients from the perspective of both primary 
care and respiratory specialist physicians. The results show that: i) no 
meaningful differences exist in the characteristics of patients prescribed 
pMDIs compared to those prescribed DPIs; ii) the strongest driver of 
inhaler choice is ICS/LABA medication. We also observed that over a 
period of 1-year, few patients were prescribed spirometry or specialist 
examinations, whereas approximately 20% of patients experienced 
deterioration in asthma and/or exacerbations. Furthermore, most of the 
specialists were aware of the difficulties encountered by patients when 
using pMDIs and DPIs, which were regarded as obstacles to achieving 
full asthma control. Finally, specialists agreed upon the need for novel 
inhaler technologies that may overcome patients’ difficulties in using 
Table 1 
Baseline characteristics of GPs’ and specialists’ asthmatic patients initiating treatment with beclometasone dipropionate/formoterol or fluticasone/salmeterol 
stratified by device type.   
GPs’ Patients Specialists’ Patients 
Total (N  4979) pMDI (N  2870) DPI (N  2109) Total (N  660) pMDI (N  379) DPI (N  281) 
Gender 
Female: N (%) 2914 (58.53%) 1.653 (57.60%) 1261 (59.79%)  380 (57.58) 217 (57.26) 163 (58.01)  
Age 
Years: Mean (SD) 48.30 (18.30) 47.30 (18.20) 49.60 (18.40) * 36.25 (16.38) 35.75 (17.21) 36.93 (15.20)  
18 yrs: N (%) 233 (4.68%) 145 (5.05%) 88 (4.17%)  84 (12.73) 61 (16.09) 23 (8.19)  
18 -| 65 yrs: N (%) 3766 (75.64%) 2.204 (76.79%) 1.562 (74.06%) * 542 (82.12) 300 (79.16) 242 (86.12) * 
>65 yrs: N (%) 980 (19.68%) 521 (18.15%) 459 (21.76%)  34 (5.15) 18 (4.75) 16 (5.69)  
Body Mass Index 
Kg/m2: Mean (SD) 26.80 (5.80) 26.50 (5.70) 27.10 (6.00) * 23.91 (3.65) 23.79 (3.51) 24.07 (3.84)  
Missing: N (%) 2222 (44.63%) 1313 (45.75%) 909 (43.10%)  0 . 0 . 0 .  
Smoking Habits 
Smokers: N (%) 513 (10.30%) 304 (10.59%) 209 (9.91%)  165 (25.00) 81 (21.37) 84 (29.89) * 
Comorbidities1 
No comorbidities: N (%) 2639 (53.00%) 1548 (53.94%) 1091 (51.73%)  530 (80.30) 304 (80.21) 226 (80.43)  
1 co-morbidity: N (%) 1345 (27.01%) 767 (26.72%) 578 (27.41%)  123 (18.64) 72 (19.00) 51 (18.15)  
2 co-morbidities: N (% 995 (19.98%) 555 (19.34%) 440 (20.86%)  7 (1.06) 3 (0.79) 4 (1.42)  
*p < 0.05 comparing pMDI vs DPI groups. DPI: dry powder inhaler; GP: general practitioner; pMDI: pressurised, metered-dose inhaler; SD: standard deviation. 
1 Co-morbidities included ischaemic heart disease, disease of the pulmonary circulation, cardiac arrhythmia, heart failure, systemic hypertension, diabetes mellitus, 
dyslipidaemia, osteoporosis, gastro-oesophageal reflux disease, allergic rhinitis, sinusitis, neurotic disorders, personality disorders and other non-psychotic mental 
disorders, and nasal polyps. 
Table 2 
Multivariate logistic models evaluating factors that may influence the choice of 
the device (DPI versus pMDI) by GPs and specialists.  
GPs (N  2757) OR [95% CI] 
Gender Female 1.00 
Male 0.96 [0.81–1.13] 
Age <18 years 1.00 
18–65 years 1.35 [0.88–2.07] 
>65 years 1.40 [0.87–2.25] 
Comorbidities No comorbidities 1.00 
1 co-morbidity 1.05 [0.86–1.28] 
At least 2 co-morbidities 0.96 [0.76–1.21]  
BMI  1.02 [1.01–1.04]* 
Medication Fluticasone/salmeterol 1.00 
Beclometasone dipropionate/formoterol 0.19 [0.16–0.23]* 
Specialists (N  289) OR [95% CI] 
Gender Female 1.00 
Male 1.19 [0.69–2.06] 
Age <18 years 1.00 
18–65 years 4.64 [1.64–13.13]* 
>65 years 11.01 [2.38–50.88]* 
Comorbidities No comorbidities 1.00 
1 comorbidity 0.95 [0.48–1.89] 
At least two comorbidities 0.65 [0.04–9.64] 
PEF  1.01 [0.99–1.03] 
Smoking No 1.00 
Yes 1.40 [0.75–2.58] 
Medication Fluticasone/salmeterol 1.00 
Beclometasone dipropionate/formoterol 0.17 [0.08–0.37]* 
*, p-value < 0.05. 
BMI: body mass index; DPI: dry powder inhaler; GP: general practitioner; PEF: 
peak expiratory flow; pMDI: pressurised, metered-dose inhaler; OR: Odds Ratio; 
CI: confidence interval. 
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Table 3 
Information collected during 12-month follow-up on GPs’ patients stratified by type of device prescribed.   
GPs’ Patients 
Total (N  4979) pMDI (N  2870) DPI (N  2109) 
Spirometry requests 
No requests: N (%) 4203 (84.41%) 2431 (84.70%) 1772 (84.02%) 
1 request: N (%) 598 (12.01%) 342 (11.92%) 256 (12.14%) 
2 requests: N (%) 145 (2.91%) 80 (2.79%) 65 (3.08%) 
3 requests: N (%) 33 (0.66%) 17 (0.59%) 16 (0.76%)  
Specialist visits and hospitalizations 
At least one pulmonologist visit request: N (%) 746 (14.98%) 431 (15.01%) 315 (14.94%) 
At least one allergologist visit request: N (%) 201 (4.04%) 108 (3.76%) 93 (4.41%) 
At least one hospitalization: N (%) 323 (6.49%) 177 (6.17%) 146 (6.92%) 
At least one emergency room access: N (%) 224 (4.50%) 126 (4.39%) 98 (4.65%)  
Exacerbations 
At least one exacerbation: N (%) 1042 (20.93%) 618 (21.53%) 424 (20.10%)  
SABA prescriptions 
No prescriptions: N (%) 3861 (77.55%) 2269 (79.06%) 1592 (75.49%) 
1 prescription: N (%) 744 (14.94%) 406 (14.15%) 338 (16.03%)* 
2 prescriptions: N (%) 216 (4.34%) 108 (3.76%) 108 (5.12%) 
3 prescriptions: N (%) 158 (3.17%) 87 (3.03%) 71 (3.37%) 
*Statistically significant difference between pMDI and DPI groups: p-value < 0.05. 
DPI: dry powder inhaler; GP: general practitioner; pMDI: pressurised metered-dose inhaler; SABA: short-acting β2-agonist. 
Fig. 2. Agreement among specialists’ on statements describing the role of inhaler devices in asthma control and adherence. A score equal to 1 expressed total 
disagreement, whereas a score equal to 10 denotes total agreement. 
Fig. 3. Mean and standard deviation scores assigned by specialists to inhaler-related factors when prescribing an inhaler device. 1 denotes “not at all important” and 
10 denotes “extremely important”. 
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currently available inhaler devices. 
To the best of our knowledge, this is the first study aimed at inves-
tigating the behaviour of Italian GPs and respiratory specialists when 
choosing an inhaler device for asthma patients treated with ICS/LABA 
medication in a real-life setting. This study adds evidence to the current 
literature [17, 18] and clinical respiratory practice [16] that, in the 
majority of patients, drug choice is usually the dominant step when 
prescribing inhaled therapy and, together with drug availability and 
reimbursement criteria, dictates the inhaler device options. Of note, we 
found that both GPs and respiratory specialists prescribed ICS/LABA 
medications via DPIs preferentially to older, smoker and obese patients, 
and that the fluticasone/salmeterol combination was more likely pre-
scribed via a DPI. Taken together, these findings may suggest a prefer-
ential use of the fluticasone/salmeterol combination in patients with 
potentially more severe disease. 
Notwithstanding this current “standard practice”, the importance of 
correct inhaler device selection as a dominant feature of the treatment 
decision is becoming increasingly recognised [6,9,16,30,31]. Although 
guidelines have lacked clarity on specific guidance regarding appro-
priate inhaler selection [32, 33], it is encouraging to see that the latest 
report on the Global Initiative for Asthma clearly states the importance 
of inhaler device selection in daily clinical practice (1). Interestingly, 
several studies have demonstrated a relationship between characteris-
tics of individual inhaler devices and the patient’s degree of adherence 
[8], and that an increased frequency of critical errors in inhalation is 
associated with worse asthma control, resulting in more disease exac-
erbations and healthcare resource consumption [11,34]. On the other 
hand, improvement of inhaler technique by effective training has been 
associated with better control of symptoms and improved quality of life 
[35,36]. Collectively, these findings indicate that it is indeed reasonable 
to hypothesise that the selection of an inhaler device tailored to the 
characteristics of the individual patient results in improved adherence 
and better clinical outcomes. The importance of factors such as aging, 
education status, cognitive status, manual dexterity and strength have 
been highlighted in previous studies [10] and a practical approach to the 
selection of the most appropriate inhaler device for each patient has 
been proposed [30,31]. Despite this, the prescribing habit of GPs and 
respiratory specialists revealed in the present study indicates that they 
still prioritise the drug over the device when initiating treatment of 
asthma patients. The reason(s) for this behaviour are not immediately 
clear, but may reflect ingrained habits rather than a conscious, 
evidence-based approach. 
Although international guidelines do recommend the measuring 
lung function periodically when managing asthma [1], in the present 
study few patients managed by general physicians were recalled for 
spirometry during the 1-year period after initiation of ICS/LABA treat-
ment, independently of the inhaler device prescribed. Similarly, the 
proportion of patients referred to a respiratory specialist was limited, 
particularly considering that more than 20% of the patients experienced 
at least one exacerbation during this same 1-year period. This finding is 
particularly meaningful considering that it is comparable to exacerba-
tion rates found in the CRITIKAL study [11], which was specifically 
aimed at collecting extensive information on asthma patients’ de-
mographic characteristics, symptoms, lung function, inhaler technique, 
and occurrence of exacerbations. Together, these findings suggest 
sub-optimal management of the disease by family doctors, particularly 
when it is considered that the patients in this study had been newly 
commenced on treatment for their disease. In another, community based 
study, it was shown that only half of the patients with a clinical diagnosis 
of asthma or COPD had ever performed a spirometry test [37]. 
Furthermore, a survey involving both GPs and asthma specialists 
showed that familiarity with, and adherence to asthma guidelines was 
higher for specialists than for primary care physicians, but was low in 
both groups for several key recommendations [38]. 
The majority of respiratory specialists interviewed in the ad-hoc 
survey agreed upon the tenet that incorrect use of inhaler devices may 
contribute to poor asthma control, with faults being attributable to 
pMDIs, as well as to DPIs. Poor confidence in the currently available 
inhalers by the interviewed specialists may be one of the underlying 
reasons for the doctors’ prescription behaviour observed in the present 
study. Therefore, it is reasonable to hypothesise that novel inhaler 
technology, potentially capable of overcoming difficulties currently 
experienced with DPIs and pMDIs, represents an opportunity to improve 
asthma control. 
Our study has some limitations, the most notable being the inherent 
selection bias in survey-based retrospective analyses. Firstly, this study 
was conducted in a single health-care system; therefore, extrapolation of 
these results to other populations should be with caution. The data do 
however show trends similar to previous research [17,18]. Furthermore, 
other European countries such as France and Spain share common fea-
tures with the Italian healthcare system, allowing our results to have 
important clinical relevance outside Italy. Secondly, the assumption that 
obtaining a prescription was equivalent to taking the prescribed medi-
cation might not be completely accurate [8]. However, rates and vol-
umes of prescriptions by GPs, such as those obtained from the Italian 
IQVIA LPD, have already been shown to be consistent with those 
measured by other data sources providing information on dispensed 
medications [21]. Thirdly, since IQVIA LPD is a secondary data re-
pository developed for purposes other than scientific research, infor-
mation about hospitalisations is not mandatory and may have been 
underestimated. 
The main strength of the present study is the opportunity to take 
advantage of very heterogeneous data sources. Using both IQVIA LPD 
and PA allowed us to gain insight from two different perspectives, that of 
family doctors and that of respiratory specialists, covering most poten-
tial prescribers of asthma treatments. The combined evaluation of evi-
dence obtained from these diverse but complementary real-world data 
allowed a more comprehensive overview. In addition, deeper insight 
offered by the ad-hoc survey served as confirmation of the need for new 
technologies such as that represented by the breath-triggered K-haler 
device. Our findings unveil GP and specialist perspectives about the role 
of the inhaler device in asthma treatment. This information could also be 
used to guide the development of next generation inhaler devices for 
respiratory disease. 
5. Conclusion 
It has been advocated that the choice of an inhalation device for drug 
administration in patients with asthma is as critical as the choice of the 
medication itself [15]. Consequently, the prescriber should be able to 
select the device based on the patient’s characteristics and needs [14]. 
However, results from the present study suggest a prescription behav-
iour that seems to be affected by habits, with doctors choosing the type 
of device in relation to the medicine prescribed, rather than based on 
patient characteristics. 
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